Condition
Congenital Bleeding Disorder
Haemophilia A
Locations
Iraq
Start date
10/11/2024
Identifiers
Trial ID
NN7008-7871,
NCT number NCT06574984,
Eudract number Not Available
NCT number NCT06574984,
Eudract number Not Available
Summary
The study has descriptive purposes, with aim of assessing how turoctocog alfa is used in the everyday practice and to provide a baseline for the management of haemophilia A and does not involve any change in the clinical management of participants. Data will be extrapolated from the existing paper based medical records and uploaded to an electronic database specifically created for the study. Baseline information/history will be recorded at time of switching from previous FVIII replacement therapy to turoctocog alfa from the enrolled participants and outcomes will be collected according to participants visit format.
Trial Overview:
Treatment
DRUG: Turoctocog alfa
Study type
OBSERVATIONAL
Trial duration
Nov 10 2024 - May 01 2025
Participants
900
Phase
Not Available
Are you eligible?
Gender
MALE
Age
Not Available
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.